Previous close | 115.50 |
Open | 115.50 |
Bid | 119.60 |
Ask | 127.90 |
Strike | 320.00 |
Expiry date | 2025-01-17 |
Day's range | 115.50 - 115.50 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Investing.com -- Gene-sequencing firm Illumina (NASDAQ:ILMN) said it would take goodwill impairment charge of $1.47 billion in its second quarter linked to its recently spun-off cancer diagnostic test manufacturer Grail (NASDAQ:GRAL).
Gene-sequencing equipment maker Illumina said it will likely recognize an additional impairment charge of about $420 million for Grail's in-process research and development intangible (IPR&D) asset in the quarter ended June. In December, activist investor Carl Icahn said Grail's greater-than-expected expenditure and delays in advancing its tests had also forced Illumina to take impairments that totaled $4.7 billion.
With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.